Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30332807 | 1.00 | KMO (0.38) | KMOSCN9ASLC6A9LIPECDK4 | |
| SCHEMBL14003560 | 0.92 | KMO (0.41) | KMOSLC6A9LIPECDK4CCND3 | |
| SCHEMBL14028801 | 0.89 | KMO (0.41) | KMOLIPECDK4CCND3GSK3B | |
| SCHEMBL14003561 | 0.88 | KDM4E (0.40) | KMOSCN9ALIPECDK4CCND3 | |
| SCHEMBL14028843 | 0.86 | KMO (0.42) | KMOLIPECDK4CCND3GSK3B | |
| SCHEMBL14028798 | 0.86 | KMO (0.43) | KMOLIPECDK4CCND3GSK3B | |
| SCHEMBL14003570 | 0.86 | KMO (0.39) | KMOSCN9ACDK4CCND3GSK3B | |
| SCHEMBL14028842 | 0.85 | KMO (0.41) | KMOLIPECDK4CCND3GSK3B | |
| SCHEMBL3138575 | 0.85 | KMO (0.38) | KMOCDK4TRPV1NOD1NOD2 | |
| SCHEMBL14003548 | 0.84 | KMO (0.39) | KMOLIPECDK4CCND3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230152314-A1 | LIPOCALIN-2 ASSAY FOR INTESTINAL ADAPTATION | THE JOHNS HOPKINS UNIVERSITY | 2023-05-18 | — | — | US | disclosed |
| US-20230095683-A1 | COPROCOCCUS BACTERIA FOR USE IN THE TREATMENT OF METABOLIC SYNDROME AND INFLAMMATORY BOWEL DISEASES | SORBONNE UNIVERSITE (FR) | 2023-03-30 | — | — | US | disclosed |
| US-11596657-B2 | Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2023-03-07 | — | — | US | disclosed |
| EP-4114420-A1 | COPROCOCCUS BACTERIA FOR USE IN THE TREATMENT OF METABOLIC SYNDROME AND INFLAMMATORY BOWEL DISEASES | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (FR) | 2023-01-11 | — | — | EP | disclosed |
| WO-2021175998-A1 | COPROCOCCUS BACTERIA FOR USE IN THE TREATMENT OF METABOLIC SYNDROME AND INFLAMMATORY BOWEL DISEASES | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) | 2021-09-10 | — | — | WO | disclosed |
| EP-3875098-A1 | USE OF COPROCOCCUS BACTERIA FOR THE TREATMENT OF METABOLIC SYNDROME AND INFLAMMATORY BOWEL DISEASES | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) | 2021-09-08 | — | — | EP | disclosed |
| US-20190282638-A1 | USE OF AHR AGONIST FOR THE PREVENTIVE OR CURATIVE TREATMENT OF METABOLIC SYNDROME AND THE ASSOCIATED DISORDERS | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) | 2019-09-19 | — | — | US | disclosed |
| EP-3522902-A1 | USE OF AHR AGONIST FOR THE PREVENTIVE OR CURATIVE TREATMENT OF METABOLIC SYNDROME AND THE ASSOCIATED DISORDERS | Institut National de la Recherche Agronomique (FR) | 2019-08-14 | — | — | EP | disclosed |
| WO-2018065132-A1 | USE OF AHR AGONIST FOR THE PREVENTIVE OR CURATIVE TREATMENT OF METABOLIC SYNDROME AND THE ASSOCIATED DISORDERS. | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2018-04-12 | — | — | WO | disclosed |
| US-9757378-B2 | Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation | UNIVERSITE DE MONTREAL (CA) | 2017-09-12 | — | — | US | disclosed |
| US-20140343051-A1 | METHODS TO MODULATE ACUTE MYELOID LEUKEMIA STEM/PROGENITOR CELL EXPANSION AND/OR DIFFERENTIATION | HOPITAL MAISONNEUVE-ROSEMONT (CA) | 2014-11-20 | — | — | US | disclosed |
| US-7759357-B2 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | WOISETSCHLAEGER MAXIMILIAN | 2008-11-13 | — | — | US | disclosed |
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | WOISETSCHLAEGER MAXIMILIAN | 2008-11-13 | — | — | US | disclosed |
| EP-1474146-B1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2007-12-06 | — | — | US | disclosed |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | BULUSU MURTY (AT) | 2005-06-02 | — | — | US | disclosed |
| EP-1474146-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | Novartis AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003063871-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | IFNG, IL2, LY96 | KMO 716/4885SCN9A 4188/4885SLC6A9 4399/4885 |
| US-20140343051-A1 | METHODS TO MODULATE ACUTE MYELOID LEUKEMIA STEM/PROGENITOR CELL EXPANSION AND/OR DIFFERENTIATION | MCL1, AHR, MYADM | KMO 185/4885SCN9A 4318/4885SLC6A9 4695/4885 |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | FCER2, SELP, FCGR2A | KMO 2307/4885SCN9A 3610/4885SLC6A9 4691/4885 |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | FCER2, SELP, FCGR2A | KMO 2307/4885SCN9A 3610/4885SLC6A9 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.